AlphAIalphai — Financial news for AI agents
Stock TitanMAR 314 min read$TBPH

Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement

Theravance Biopharma, Inc. announced a settlement of patent litigation concerning its YUPELRI® (revefenacin) inhalation solution with Mankind Pharma. This agreement grants Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. beginning April 23, 2039. The resolution clarifies the long-term exclusivity of YUPELRI and eliminates legal uncertainties, though it is subject to review by U.S. antitrust authorities.

Original reporting
Stock Titan
Published Mar 31, 2026, 4:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TBPH
Neutral
medium confidence
Mentioned
$TBPH
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$TBPHNeutralMed
01

Why it matters

Legal settlement reduces patent litigation risks, providing clarity for future sales and licensing strategies.

02

Market read

The settlement is a significant legal development with potential long-term implications for Theravance's revenue stability.

03

What to watch

Potential delays in product commercialization or regulatory changes could offset benefits.

Timing: Long-term relevance, as the patent expiry is set for 2039.

Background

Theravance Biopharma's YUPELRI is a key inhalation therapy with patent protection until 2039.

Company-level read

Ticker impact

$TBPHNeutralMedium confidence
Context

High relevance due to direct impact on company's patent and product pipeline.

Expected impact

Minimal short-term price movement; potential long-term positive impact due to legal clarity.

Evidence & confidence

While the patent settlement reduces legal uncertainties, the actual market impact depends on subsequent sales performance and competitive responses.

Market effects

Sector

Possible stabilization of the life sciences sector, with reduced patent litigation risks.

Regional

Primarily US-focused, with limited immediate regional effects.

Global

Low; the impact is specific to the company's patent and product portfolio.

Counterpoint

What could challenge this read

The settlement might signal potential future legal challenges or market skepticism about long-term exclusivity.

Key entities

  • Company
    Theravance Biopharma, Inc.

    A biopharmaceutical company specializing in respiratory medicines.

  • Company
    Mankind Pharma

    A pharmaceutical company involved in the patent settlement.

  • Product
    YUPELRI (revefenacin)

    A respiratory inhalation solution used in COPD treatment.

Read at source← All news

Related articles

JUL 21
$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min
JUN 30
$ZYMEHighAI 9/10

Vancouver biotech Zymeworks buying Theravance for US$929M

Zymeworks Inc. (Nasdaq:ZYME) said it will pay $929M in cash to acquire Theravance Biopharma Inc. (Nasdaq:TBPH). The offer is $17 per Theravance share, 3.6% below the prior close. Theravance’s ampreloxetine failed a March trial; its only marketed drug is Yupelri. Deal includes a one-year ampreloxetine monetization split and about $2.5B in Irish tax attributes.

castanetkamloops.net4 min
AUG 8
$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

worldoil.com3 min
AUG 8
$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

worldoil.com4 min